Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
Contents:; Cellular mechanisms of chemotherapy -- Pharmacologic principles of chemotherapy -- Pharmacogenomics and chemotherapy -- Principles and standards of antineoplastic therapy administration -- Administration of hazardous drugs in the perioperative setting -- Immunotherapy : agents and target…
Contents:; 1: Basis of Carcinogenesis; 2: Epidemiology and Prevention; 3: Evidence-Based Nursing in Basic Anticancer Treatment: Management of the Most Important Side Effects; 4: The Patients? Journey with Targeted Therapies; 5: Immunotherapy: New Challenges for Nursing; 6: Robotic Surgery; 7: Relat…
Contents:; Physical activity and cancer survival -- Promoting physical activity for cancer survivors -- FITT principle for physical activity -- Assessing readiness for physical activity -- Assessing readiness for physical activity : physical -- Considerations -- Evaluating tolerance and adherence t…
Version 4.0 published: May 28, 2009 (v4.03: June14, 2010)."
This publication represents the views and expert; opinions of an IARC Working Group on the; Evaluation of Carcinogenic Risks to Humans,; which met in Lyon, February 2013.
This publication represents the views and expert; opinions of an IARC Working Group on the; Evaluation of Carcinogenic Risks to Humans which met in Lyon (France) June 3 -10, 2014.
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June 2015
Table of contents:; History of Cancer Immunotherapy -- Section I: Basic Principles of Tumor Immunology -- Section II: Cancer Immunotherapy Targets and Classes -- Section III: Immune Function in Cancer Patients -- Section IV: Disease-Specific Treatments and Outcomes -- Section V: Regulatory Aspects …
Table of Contents:; Chapter 1 -- Translation in Immunology: The Role of Translational Biomarkers to Guide Clinical Use of Immunotherapy for Cancer -- Chapter 2 Monoclonal Antibody Therapy -- Chapter 3 Somatic Mutations and Immunotherapy -- Chapter 4 Checkpoint Blockade -- Chapter 5 Myeloid Leukemia…
Table of Contents:; I OVERVIEW -- II DIAGNOSTIC STUDIES -- III NERVOUS SYSTEM INVOLVEMENT OF SYSTEMIC CANCERS -- IV NEUROLOGICAL COMPLICATIONS OF CANCER -- V NEUROLOGICAL COMPLICATIONS OF CANCER THERAPY -- NEUROLOGICAL COMPLICATIONS OF SPECIFIC MALIGNANCIES -- VII NEUROLOGICAL COMPLICATIONS IN LONG…